Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP15L Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5)

Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.

Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-HER2, Anti-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus, Anti-Human Epidermal Growth Factor

OP15L
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

Species ReactivityHostAntibody Type
H, MMMonoclonal Antibody

Products

Katalogové čísloBalení ks/bal.
OP15L-100UG Skleněná láhev 100 μg
Description
OverviewRecognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
Catalogue NumberOP15L
Brand Family Calbiochem®
SynonymsAnti-HER2, Anti-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus, Anti-Human Epidermal Growth Factor
Application Data
Detection of human c-ErbB2/c-Neu by immunoblotting. Sample: Whole cell lysate from HEK293 cells. Primary antibody: Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) (Cat. No. OP15L) (1 µg/ml). Detection: chemiluminescence.
References
ReferencesMamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
Tetu, B., et al. 1994. Cancer 73, 2359.
DiFiore, P.P., et al. 1987. Science 237, 178.
Slamon, D.J., et al. 1987. Science 235, 177.
Varley, J.M., et al. 1987. Oncogene 1, 423.
Bargmann, C.I., et al. 1986. Nature 319, 226.
Yamamoto, T., et al. 1986. Nature 319, 230.
Blick, M., et al. 1984. Blood 64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
Product Information
FormLyophilized
FormulationLyophilized from 20 mM ammonium bicarbonate Buffer, 100 µg FAF-BSA.
Negative controlHepG2 cells or normal skin
Positive controlSK-BR-3 cells or breast carcinoma tissue
PreservativeNone
Quality LevelMQ100
Applications
Application ReferencesParaffin Sections Meissner, K., et al. 1990. Am. J. Pathol. 137, 1305. Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Original Clone Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Immunohistochemistry, Immunoblotting Zhau, H.E., et al. 1990. Mol. Carcinogen. 3, 254. Immunoprecipitation Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239.
Key Applications Frozen Sections
Immunoblotting (Western Blotting)
Immunofluorescence
Immunoprecipitation
Paraffin Sections
Application NotesFrozen Sections (2.5 µg/ml)
Immunoblotting (2.5 µg/ml, see application references)
Immunofluorescence (2.5 µg/ml)
Immunoprecipitation (1 µg per sample, see application references)
Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required, see application references)
Application CommentsFor paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
ImmunogenHuman
Clone3B5
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
  • Mouse
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsReconstitue the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Freezing of aliquots is best for long term storage of reconstituted product; repetitive freezing and thawing should be avoided.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
OP15L-100UG 04055977224641

Documentation

Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) MSDS

Title

Safety Data Sheet (SDS) 

Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) Certificates of Analysis

TitleLot Number
OP15L

References

Přehled odkazů
Mamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
Tetu, B., et al. 1994. Cancer 73, 2359.
DiFiore, P.P., et al. 1987. Science 237, 178.
Slamon, D.J., et al. 1987. Science 235, 177.
Varley, J.M., et al. 1987. Oncogene 1, 423.
Bargmann, C.I., et al. 1986. Nature 319, 226.
Yamamoto, T., et al. 1986. Nature 319, 230.
Blick, M., et al. 1984. Blood 64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.

Citations

Název
  • Rita Nahta, et al. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65, 11118-11128.
    		•
    Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision02-October-2007 RFH
    SynonymsAnti-HER2, Anti-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus, Anti-Human Epidermal Growth Factor
    ApplicationFrozen Sections (2.5 µg/ml)
    Immunoblotting (2.5 µg/ml, see application references)
    Immunofluorescence (2.5 µg/ml)
    Immunoprecipitation (1 µg per sample, see application references)
    Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required, see application references)
    Application Data
    Detection of human c-ErbB2/c-Neu by immunoblotting. Sample: Whole cell lysate from HEK293 cells. Primary antibody: Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5) (Cat. No. OP15L) (1 µg/ml). Detection: chemiluminescence.
    DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-Neu protein.
    BackgroundAmplification of the human proto-oncogene c-neu has been reported to occur in approximately 30% of breast carcinomas and measurement of the amplification has been proposed as a useful predictor of disease prognosis. Gene amplification and the resulting overexpression of proto-oncogene encoded p185c-neu is thought to transform cells by chronically stimulating signal transduction pathways, and in model systems overexpression of human c-neu induces cellular transformation. In the rat model system, a point mutation has been located within the transmembrane domain of the c-neu oncogene. neu (from neuroglioblastomas) is also referred to as erbB-2 (from erythroblastosis virus) and HER2 (for Human Epidermal Growth Factor Receptor) and was the second of four members of the EGF receptor family to be described.
    HostMouse
    Immunogen speciesHuman
    Immunogena synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
    Clone3B5
    IsotypeIgG₁
    Specieshuman, mouse
    Positive controlSK-BR-3 cells or breast carcinoma tissue
    Negative controlHepG2 cells or normal skin
    FormLyophilized
    FormulationLyophilized from 20 mM ammonium bicarbonate Buffer, 100 µg FAF-BSA.
    PreservativeNone
    CommentsFor paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
    Storage +2°C to +8°C
    Do Not Freeze Ok to freeze
    Special InstructionsReconstitue the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Freezing of aliquots is best for long term storage of reconstituted product; repetitive freezing and thawing should be avoided.
    Toxicity Standard Handling
    ReferencesMamcs, J.R., et al. 1994. Ann. Surg. 219, 332.
    Tetu, B., et al. 1994. Cancer 73, 2359.
    DiFiore, P.P., et al. 1987. Science 237, 178.
    Slamon, D.J., et al. 1987. Science 235, 177.
    Varley, J.M., et al. 1987. Oncogene 1, 423.
    Bargmann, C.I., et al. 1986. Nature 319, 226.
    Yamamoto, T., et al. 1986. Nature 319, 230.
    Blick, M., et al. 1984. Blood 64, 1234.
    Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
    Citation
  • Rita Nahta, et al. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 65, 11118-11128.
    		•
    Application referencesParaffin Sections Meissner, K., et al. 1990. Am. J. Pathol. 137, 1305. Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Original Clone Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239. Immunohistochemistry, Immunoblotting Zhau, H.E., et al. 1990. Mol. Carcinogen. 3, 254. Immunoprecipitation Van De Vijver, J.J., et al. 1988. New Engl. J. Med. 319, 1239.